Spanish researchers have sounded the alarm that rates of liver cancer are rising dramatically among people with HIV, solely as a result of vir...

Tenofovir is safe and effective for long-term treatment of hepatitis B, and leads to few kidney-related side effects and no clinically relevan...

The new therapy simeprevir is generally safe and well-tolerated among hep C patients with advanced liver fibrosis and improves treatment outco...

A combination of daclatasvir and sofosbuvir produced cures in more than 93 percent of hepatitis C patients, with or without the addition of ri...

Danoprevir and mericitabine, two experimental hepatitis C therapies, proved safe and effective among patients with previous treatment experien...

Bristol-Myers Squibb?s triple combination hepatitis C therapy showed a 94 percent cure rate in hard-to-treat patients.

People coinfected with HIV and hepatitis C virus experience high hepatitis cure rates from an Incivek (telaprevir)-based triple combination th...

Gilead Sciences? pair of investigatory hepatitis C virus therapies led to a 100 percent cure rate among a small cohort of patients.

Abbott Laboratories’ three-drug regimen cured 97 percent of treatment-naive hepatitis C patients and 93 percent of those who had failed a prev...